Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V-Immune vs Immuglo in Primary Immunodeficiency Disease
NCT07017036Phase 3Not yet recruiting
- Sponsor
- Virchow Group
- Start
- Jul 2025
- Primary completion
- Dec 2026
- Modality
- Recombinant Proteins and Enzymes, Tissue Cells
- Countries
- 1
01
Overview
A Phase 3 trial of IVIG-VImmune in primary immunodeficiency disease (PID), sponsored by Virchow Group. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
IVIG-VImmune
03
Conditions
primary immunodeficiency disease (PID)
Beyond the preview
Go deeper on NCT07017036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07017036.